Provider Summary
Primary Uses
Chronic refractory gout in adults who have failed or cannot tolerate conventional urate-lowering therapy.
Mechanism of Action
Pegylated uricase enzyme converts uric acid to allantoin for renal excretion.
Pre-treatment / Baseline Requirement
Screen for G6PD deficiency prior to starting; baseline serum uric acid; premedication and close monitoring for infusion reactions; discontinue if uric acid rises suggesting loss of response.
Common side effects
Infusion reactions, nausea, bruising, nasopharyngitis.
Serious adverse effects / key risks
Boxed warnings: anaphylaxis and infusion reactions; hemolysis/methemoglobinemia in G6PD deficiency.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Chronic refractory gout in adults who have failed or cannot tolerate conventional urate-lowering therapy.
How it works
Pegylated uricase enzyme converts uric acid to allantoin for renal excretion.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Infusion reactions, nausea, bruising, nasopharyngitis.
Get urgent help for:
Boxed warnings: anaphylaxis and infusion reactions; hemolysis/methemoglobinemia in G6PD deficiency.
On treatment Day:
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.